Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Amedisys (AMED) PT Raised to $126 at RBC Capital
October 31, 2018 6:59 AM EDTRBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $126.00 (from $115.00) while maintaining an Outperform rating.
Morgan noted a strong Q3, with momentum in 2019.
... MoreAmedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
October 29, 2018 5:02 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.95, $0.18 better than the analyst estimate of $0.77. Revenue for the quarter came in at $417.3 million versus the consensus estimate of $411.2 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $3.54-$3.60, versus the consensus of $3.40. Amedisys sees... More
